# Neurelis, Inc.

> Neurelis is a San Diego neuroscience company that commercialized VALTOCO, a prescription diazepam nasal spray for seizure clusters in people ages 2 and older, then broadened the underlying Intravail absorption technology into a platform used in partnered products and an internal neurology pipeline. Its edge is not a newly discovered active ingredient; it is formulation, delivery, clinical execution, market access and the practical redesign of rescue treatment for patients and care partners outside a hospital.

- **Founded:** 2007
- **Headquarters:** San Diego, United States
- **Founders:** Craig C. Chambliss (President, CEO and Co-Founder), David Hale (Co-Founder and Director)
- **Team size:** Approximately 190 employees based on supplied company data; public company directories generally place Neurelis in the 101-200 range.
- **Products:** VALTOCO (diazepam nasal spray), Intravail, ProTek, Hydrogel, NRL-1004
- **Notable:** FDA approval of VALTOCO in January 2020 for seizure clusters in patients ages 6 and older., FDA orphan drug exclusivity based on clinical superiority of the intranasal route over rectal diazepam gel as a contribution to patient care., Expanded FDA approval in April 2025 to include children ages 2-5.

## Products & services

- **VALTOCO (diazepam nasal spray)** — FDA-approved prescription rescue treatment for seizure clusters distinct from a patient's usual pattern, for people with epilepsy ages 2 and older. It uses Intravail absorption-enhancement technology.
- **Intravail** — A proprietary transmucosal absorption-enhancement technology for noninvasive delivery of small molecules, peptides and proteins; used in Neurelis and partner products.
- **ProTek** — Aegis-originated excipient technology designed to stabilize proteins and peptides; acquired by Neurelis with Aegis Therapeutics.
- **Hydrogel** — Aegis-originated noninvasive drug-delivery and stabilization technology acquired with Aegis Therapeutics.
- **NRL-1004** — Investigational noninvasive formulation for acute agitation using Intravail technology; not FDA approved.
- **NRL-1049** — Investigational Phase 1 Rho kinase inhibitor being developed for cerebral cavernous malformations; not FDA approved.

## Achievements

- FDA approval of VALTOCO in January 2020 for seizure clusters in patients ages 6 and older.
- FDA orphan drug exclusivity based on clinical superiority of the intranasal route over rectal diazepam gel as a contribution to patient care.
- Expanded FDA approval in April 2025 to include children ages 2-5.
- More than 12,000 patients ages 2-5 prescribed VALTOCO after label expansion, according to the company's January 2026 update.
- Estimated 2025 net sales of $295M-$300M, more than double 2024, with reported EBITDA margin above 30%.
- Multiple U.S. patents extending elements of the VALTOCO portfolio through 2032, according to the company.
- Craig Chambliss named an EY Entrepreneur Of The Year 2026 Pacific Southwest award winner.
- Three partnered FDA-approved products listed by Neurelis use Intravail: TOSYMRA, neffy and OPVEE.

## Latest updates

- **2025-04** — FDA approved VALTOCO for children ages 2-5, expanding the indicated population to ages 2 and older.
- **2025-11** — Neurelis presented Phase 1 NRL-1049 data showing dose-proportional exposure and a favorable safety profile in the study.
- **2026-01** — Company estimated 2025 net sales of $295M-$300M, a 30%+ EBITDA margin, more than $175M cash and no bank debt.
- **2026-04** — Neurelis announced AAN presentations on seizure termination and healthcare-resource utilization associated with diazepam nasal spray.
- **2026-06** — CEO and co-founder Craig Chambliss received an EY Entrepreneur Of The Year 2026 Pacific Southwest award.

## Links

- Website: https://www.neurelis.com/
- LinkedIn: https://www.linkedin.com/company/neurelis-inc./
- Twitter/X: https://twitter.com/NeurelisInc
- Instagram: https://www.instagram.com/neurelis/
- Facebook: https://www.facebook.com/NeurelisInc/

---

Profile page: https://yespress.io/neurelis-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-21